UBE3A and Angelman syndrome: In an Angelman syndrome mouse model, intracerebroventricular (ICV) injection of ASOs, directed against the long non-coding RNA UBE3A antisense transcript (UBE3A-ATS), could help to restore UBE3A protein levels, which contributes to alleviate part of the cognitive deficits associated with the disease [176].